Advent Venture Raises $120 Million for First Life Sciences Fund
Advent Venture Partners LLP, a London-based investment firm, has raised $120 million for its first life science fund.
The fund will invest in early- to mid-stage life science companies in the U.K., Europe and U.S. and will be managed by partners Shahzad Malik and Raj Parekh, Advent said in an e- mailed statement today.
Advent has invested in PowderMed, which was bought by Pfizer Inc.; Thiakis, which was purchased by Wyeth, and Respivert, which was bought by Johnson & Johnson.
To contact the editors responsible for this story: Phil Serafino at firstname.lastname@example.org